Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.013

10 - Zuclopenthixol and Zuclopenthixol Decanoate; Flupenthixol and Flupenthixol Decanoate

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

As with many first-generation antipsychotics (FGAs), zuclopenthixol and flupenthixol have no unique therapeutic benefit compared to other D2 antagonists, but have long-acting injectable (LAI) preparations available in certain parts of the world and a modest database of plasma level information. In addition to an LAI formulation, zuclopenthixol also has an injectable formulation (zuclopenthixol acetate) that provides therapeutic levels over several days, with a time to peak plasma levels (Tmax) of 24–48 hours [1].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 201 - 216

DOI: https://doi.org/10.1017/9781009002103.013 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Lundbeck Canada Inc. (2016). Clopixol, Clopixol-Acuphase, Clopixol Depot product monograph. St. Laurent, Canada.Google Scholar

Jørgensen, A., Aaes-Jørgensen, T., Gravem, A., et al. (1985). Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology (Berl), 87, 364–367.Google Scholar

Amdisen, A., Aaes-Jørgensen, T., Thomsen, N. J., et al. (1986). Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology (Berl), 90, 412–416.Google Scholar

Szukalski, B., Lipska, B., Welbel, L., et al. (1986). Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology (Berl), 89, 428–431.Google Scholar

Nyberg, S., Farde, L., Bartfai, A., et al. (1995). Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol, 10, 221–227.Google Scholar

Balant-Gorgia, A. E., Balant, L. P., Gex-Fabry, M., et al. (1987). Stereoselective disposition of flupenthixol: influence on steady-state plasma concentrations in schizophrenic patients. Eur J Drug Metab Pharmacokinet, 12, 123–128.Google Scholar

Reimold, M., Solbach, C., Noda, S., et al. (2007). Occupancy of dopamine D (1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupenthixol in comparison with risperidone and haloperidol. Psychopharmacology, 190, 241–249.Google Scholar

Baumann, P., Kirchherr, H., Berney, P., et al. (2012). Flupenthixol: relevance of stereoselective therapeutic drug monitoring. Psychopharmacology (Berl), 221, 719–720.Google Scholar

Davies, S. J., Westin, A. A., Castberg, I., et al. (2010). Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand, 122, 444–453.Google Scholar

Balant-Gorgia, A. E., Eisele, R., Aeschlimann, J. M., et al. (1985). Plasma flupenthixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit, 7, 411–414.Google Scholar

Walter, S., Bauer, S., Roots, I., et al. (1998). Quantification of the antipsychotics flupenthixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl, 720, 231–237.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, http://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Gex-Fabry, M., Balant-Gorgia, A. E., and Balant, L. P. (1997). Therapeutic drug monitoring databases for postmarketing surveillance of drug–drug interactions: evaluation of a paired approach for psychotropic medication. Ther Drug Monit, 19, 1–10.Google Scholar

Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629–651.Google Scholar

Linnet, K. and Wiborg, O. (1996). Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit, 18, 629–634.Google Scholar

Balant-Gorgia, A. E. and Balant, L. (1987). Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet, 13, 65–90.Google Scholar

Lundbeck Limited (2017). Depixol Tablets 3 mg – summary of product characteristics. St Albans, UK.Google Scholar

Wójcikowski, J., Pichard-Garcia, L., Maurel, P., et al. (2004). The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol, 14, 199–208.Google Scholar

Paulzen, M., Haen, E., Hiemke, C., et al. (2017). Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol, 83, 1668–1675.Google Scholar

Norlén, M. and Allard, P. (1997). [3H]GBR 12935 binding in platelets: a possible association with cytochrome P-450IID6? Eur J Pharmacol, 332, 227–230.Google Scholar

Kapur, S., Zipursky, R., Roy, P., et al. (1997). The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 131, 148–152.Google Scholar

Lundbeck Australia (2020). Fluanxol Depot and Fluanxol Concentrated Depot package insert. North Ryde, NSW, Australia.Google Scholar

Bailey, L. and Taylor, D. (2019). Estimating the optimal dose of flupenthixol decanoate in the maintenance treatment of schizophrenia – a systematic review of the literature. Psychopharmacology (Berl), 236, 3081–3092.Google Scholar

Jann, M. W., Ereshefsky, L., and Saklad, S. R. (1985). Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet, 10, 315–333.Google Scholar

Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl, 52, S13–19.Google Scholar

Lambert, T. and Taylor, D. (2016). Pharmacology of antipsychotic long-acting injections. In Haddad, P., Lambert, T., and Lauriello, J., eds., Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press, pp. 31–57.Google Scholar

Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar

Bjørndal, F. and Aaes-Jørgensen, T. (1984). Serum concentration in acute paranoid psychosis treated with cis(Z)-clopenthixol. Nord Psykiatr Tidsskr 38, 229–233.Google Scholar

Solgaard, T., Kistrup, K., Aaes-Jørgensen, T., et al. (1994). Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients: minimum effective dose and corresponding serum levels. Pharmacopsychiatry, 27, 119–123.Google Scholar

Kistrup, K., Gerlach, J., Aaes-Jorgensen, T., et al. (1991). Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients: serum levels at the minimum effective dose. Psychopharmacology, 105, 42–48.Google Scholar

Viala, A., Ba, B., Durand, A., et al. (1988). Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl), 94, 293–297.Google Scholar

Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500–505.Google Scholar

Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar

Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255–261.Google Scholar